Wugen is dedicated to developing off-the-shelf CAR-T cell therapies for treatment of T-cell leukemias and lymphomas, Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).
These cell therapy drugs originate from healthy donors and, where appropriate, they are amplified in order to maintain the attack on cancer cells. Our technology also offers Immuno-Oncology (I/O) therapies for treatment of AML and MM.
At Wugen, we are focused on:
- Off-the-shelf CAR-T targeting T-cell malignancies
- Off-the-shelf CAR-T & I/O therapies targeting AML and MM
- Safe and effective expansion of CAR-T for the duration of cancer treatment
Our issued and pending patents support and protect a strong pipeline of cancer therapies offered to patients with high risk cancers.